ISRG stock holds steady as Intuitive Surgical awaits fresh catalyst

Intuitive Surgical stock tracks a period of steady fundamentals as investors weigh the latest disclosed operating base and the companys market value. The shares remain tied to procedure growth, installed systems, and margin trends.

Intuitive Surgical, Inc. (US4612021034) stock remains closely linked to its installed base, recurring procedure growth, and margin profile, with the last disclosed company context still centered on its da Vinci franchise and a large global system footprint.

Installed base matters

Intuitive Surgical reported 9,203 da Vinci systems installed worldwide as of the latest disclosed company context, and that scale still shapes how investors assess the business. The company also said it had 1,709 Ion systems installed, adding another growth line beyond surgical robotics.

The same company context showed 44,000 procedures performed with Ion in 2024, a concrete reminder that utilization, not just system count, drives the model. For a business built on recurring use, that 2024 procedure figure matters as much as the hardware fleet.

Margins and volume

Intuitive Surgical said 2024 revenue reached $8.35 billion, up from $7.10 billion in 2023. That 17.6% increase gives investors a clean comparison point for the pace of expansion.

The company also reported 2024 net income of $2.32 billion versus $1.88 billion in 2023, while diluted EPS rose to $6.37 from $5.08. Those figures show that earnings growth kept pace with the top line, not just the installed base.

Operating margin and procedure volume remain the central variables for 2026 because the model depends on both capital placements and recurring usage. A larger fleet is useful, but higher utilization turns that fleet into revenue.

Revenue up 17.6%

Revenue growth of 17.6% in 2024 is the clearest quantified comparison in the latest company context, and it is the number that best frames the stock today. The market typically assigns a premium to that combination of scale, profitability, and recurring use.

At the same time, the companys robotics-led mix means new procedure adoption can shift sentiment faster than the absolute number of systems sold. That is why the installed base and procedure totals remain the most useful operating metrics.

Da Vinci still anchors

The da Vinci platform remains the companys core commercial engine, and the latest disclosed installed base of 9,203 systems shows how deeply embedded it is in hospital workflows. That scale also explains why investor attention stays on procedure growth and margin discipline rather than on one-off product headlines.

Ion adds a second operating lever, with 1,709 installed systems and 44,000 procedures in 2024. Together, those figures show why the company is still evaluated as a platform business rather than as a single-product story.

Stock context stays valuation-led

For Intuitive Surgical stock, the valuation debate usually turns on whether future procedure growth can justify the premium multiple that comes with a high-margin platform model. The latest company figures provide the needed base: $8.35 billion in 2024 revenue, $2.32 billion in 2024 net income, and 2024 diluted EPS of $6.37.

The most useful market lens remains the relationship between recurring procedure volumes and earnings power. That link is what keeps the shares sensitive to every update in utilization, placements, and margin direction.

Robotic surgery base

Intuitive Surgical has built its business around surgical robotics, with da Vinci in the operating room and Ion extending the company into robotic-assisted biopsy and lung diagnostics. Those two platforms are the most relevant product references because they tie directly to the 2024 operating figures.

From an investor perspective, the product mix matters because it supports both revenue growth and recurring use. The companys 2024 figures suggest that the installed base continues to do the heavy lifting.

Market value backdrop

The companys market capitalization stood at about $173 billion as of the latest market context available in this session. That scale reflects both profitability and the long runway implied by a 9,203-system da Vinci base and 2024 revenue of $8.35 billion.

As of 21 July 2026, the stock was not accompanied by a fresh company release in the available results, so the clearest read still comes from the latest disclosed operating metrics and market value backdrop.

Intuitive Surgical stock snapshot

• Company: Intuitive Surgical, Inc.
• ISIN: US4612021034
• Ticker: NASDAQ: ISRG
• Trading venue: NASDAQ
• Market capitalization: about $173 billion (as of 21 July 2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: S&P 500